This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPEB59082_M.jpg
MaxCyte, Inc., (MXCT) 19% LOWER; sees Q3 total revenue of $7.8 – 8.0 million in the third quarter of 2023, a decrease of 25 -27% compared to the third quarter of 2022; the decline is due to continued reduced customer activity in the sector. The consensus is $11.35 million.
Accolade (ACCD) 8% LOWER; reported Q2 EPS of ($0.43), $0.11 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $96.9 million versus the consensus estimate of $94.09 million. Accolade sees Q3 2024 revenue of $95-97 million, versus the consensus of $96.6 million.
BlackBerry Limited (NYSE:BB) 4% HIGHER; the Board has determined that separating the IoT and Cybersecurity business units into two independently-operated entities is the optimal strategic direction for BlackBerry.
ALX Oncology Holdings Inc., (Nasdaq: ALXO) 3% HIGHER; announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.
The Clorox Company (NYSE:CLX) 3% LOWER; Q1 net sales are expected to decrease by 28% to 23% from the year-ago quarter. Adjusted EPS is expected to be a loss of $0.40 to $0.00, as the impact from the cybersecurity attack more than offset the benefits of pricing, cost savings and supply chain optimization. Consensus sees Q1 EPS of $1.36.
